Powder: -20°C for 3 years | In solvent: -80°C for 1 year
EZH2-IN-9 is a potent inhibitor of EZH2, whose overexpression or mutations in the SET region (Y641F, Y641N, A687V, A677G point mutations) cause abnormal elevations in H3K27me3 and contribute to the growth and development of many tumours (e.g. breast cancer, prostate cancer, leukaemia, etc.). EZH2-IN-9 has shown potential for cancer research.
パッケージサイズ | 在庫状況 | 単価(税別) |
---|---|---|
25 mg | 約6-8 週間 | ¥ 491,500 |
50 mg | 約6-8 週間 | ¥ 639,500 |
100 mg | 約6-8 週間 | ¥ 808,000 |
説明 | EZH2-IN-9 is a potent inhibitor of EZH2, whose overexpression or mutations in the SET region (Y641F, Y641N, A687V, A677G point mutations) cause abnormal elevations in H3K27me3 and contribute to the growth and development of many tumours (e.g. breast cancer, prostate cancer, leukaemia, etc.). EZH2-IN-9 has shown potential for cancer research. |
分子量 | 596.09 |
分子式 | C28H32ClF2N3O5S |
CAS No. | 2700897-24-9 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
EZH2-IN-9 2700897-24-9 Inhibitor inhibitor inhibit